Sleep and Circadian Dysfunction as Driver of Neurodegeneration
Background and Rationale
This clinical study investigates whether sleep and circadian rhythm disruption actively drives neurodegeneration rather than being merely a symptom. The study employs a longitudinal design with cognitively normal adults at genetic risk for AD (APOE4 carriers).
Protocol: 500 participants (ages 50-65, APOE4+, cognitively normal) undergo: (1) 2-week actigraphy + sleep diary at baseline, 12mo, 24mo, 36mo. (2) Polysomnography with slow-wave sleep (SWS) quantification at each timepoint. (3) Melatonin onset sampling (DLMO) to assess circadian phase. (4) CSF sampling at baseline and 36mo for amyloid-beta42, phospho-tau181, neurofilament light chain. (5) Amyloid PET at baseline and 36mo.
...Sleep and Circadian Dysfunction as Driver of Neurodegeneration
Background and Rationale
This clinical study investigates whether sleep and circadian rhythm disruption actively drives neurodegeneration rather than being merely a symptom. The study employs a longitudinal design with cognitively normal adults at genetic risk for AD (APOE4 carriers).
Protocol: 500 participants (ages 50-65, APOE4+, cognitively normal) undergo: (1) 2-week actigraphy + sleep diary at baseline, 12mo, 24mo, 36mo. (2) Polysomnography with slow-wave sleep (SWS) quantification at each timepoint. (3) Melatonin onset sampling (DLMO) to assess circadian phase. (4) CSF sampling at baseline and 36mo for amyloid-beta42, phospho-tau181, neurofilament light chain. (5) Amyloid PET at baseline and 36mo.
Primary Outcome: Correlation between SWS reduction rate and amyloid PET SUVr change over 3 years. Secondary: Circadian phase shift magnitude vs. CSF biomarker trajectories. Success Criteria: If SWS decline >20% predicts amyloid accumulation with OR>2.0 (p<0.01) after controlling for age, sex, and APOE genotype, the causal hypothesis is supported. Expected Timeline: 4 years (1yr enrollment + 3yr follow-up). Estimated Cost: $8.5M.
This experiment directly tests predictions arising from the following hypotheses:
- Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation
- Circadian Glymphatic Rescue Therapy (Melatonin-focused)
- Circadian-Synchronized Proteostasis Enhancement
- Sleep Spindle-Synaptic Plasticity Enhancement
- Biorhythmic Interference via Controlled Sleep Oscillations
Experimental Protocol
Phase 1: Participant Recruitment and Baseline Assessment (Weeks 1-4)• Recruit 300 cognitively healthy adults aged 50-75 years through community outreach and medical centers
• Screen participants using Mini-Mental State Examination (MMSE ≥26) and exclude those with existing neurological conditions
• Obtain comprehensive medical history, medication review, and informed consent
• Conduct baseline cognitive assessment using Montreal Cognitive Assessment (MoCA) and neuropsychological battery
• Collect baseline blood samples for biomarker analysis (Aβ40, Aβ42, p-tau181, NfL)
• Perform baseline brain MRI with structural and DTI sequences
Phase 2: Sleep and Circadian Monitoring (Weeks 5-8)
• Deploy 14-day actigraphy monitoring using wrist-worn ActiGraph GT9X devices
• Conduct overnight polysomnography (PSG) at sleep laboratory for 2 consecutive nights
• Measure circadian markers: salivary melatonin profiles (6 samples over 24h), core body temperature
• Administer Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale
• Assess circadian chronotype using Munich Chronotype Questionnaire
• Monitor sleep architecture parameters: REM sleep %, slow-wave sleep %, sleep efficiency
Phase 3: Longitudinal Follow-up (Months 3-36)
• Conduct quarterly cognitive assessments using comprehensive neuropsychological battery
• Repeat brain MRI at 12, 24, and 36 months to measure hippocampal volume and cortical thickness
• Collect blood biomarkers every 6 months for longitudinal tracking
• Perform annual lumbar puncture in consenting participants (n=150) for CSF biomarkers
• Continuous sleep monitoring using home-based devices every 6 months
• Track incident mild cognitive impairment (MCI) and dementia diagnoses
Phase 4: Data Analysis and Correlation (Months 37-42)
• Analyze sleep-wake cycle parameters using cosinor analysis and non-parametric circadian rhythm analysis
• Correlate sleep dysfunction metrics with rate of cognitive decline using mixed-effects models
• Examine associations between circadian disruption and neuroimaging changes
• Assess sleep quality as predictor of biomarker progression using survival analysis
• Control for confounders: age, sex, education, APOE4 status, comorbidities
Expected Outcomes
Sleep Architecture Deterioration: Participants with <15% slow-wave sleep and >30% sleep fragmentation will show 2-fold increased rate of cognitive decline compared to good sleepers (effect size d=0.6)
Circadian Rhythm Disruption: Individuals with circadian amplitude <0.3 and phase delays >2 hours will demonstrate 40% greater hippocampal atrophy rate (2.5% vs 1.8% annual volume loss)
Biomarker Progression: Poor sleepers (PSQI >10) will exhibit 50% faster increase in plasma p-tau181 levels and 30% greater Aβ42/40 ratio decline over 36 months
MCI Conversion Risk: Sleep efficiency <75% and REM sleep <15% will predict 3-fold higher risk of MCI conversion (HR=3.2, 95% CI: 1.8-5.7)
Dose-Response Relationship: Each 10% decrease in sleep efficiency will correlate with 0.2 point annual decline in MoCA scores and 1.5% additional hippocampal volume loss
CSF Biomarker Changes: Severely disrupted sleepers will show 25% higher CSF tau/Aβ42 ratios and 40% elevated neurofilament light levels compared to normal sleepersSuccess Criteria
•
Primary Endpoint Achievement: Significant association between sleep dysfunction composite score and cognitive decline rate with p<0.001 and effect size Cohen's d≥0.5
• Biomarker Validation: At least 3 of 4 neurodegeneration biomarkers show significant correlation with sleep parameters (p<0.01) with AUC≥0.70 for prediction models
• Longitudinal Consistency: Sleep-cognition associations remain significant after controlling for age, education, APOE4 status with adjusted R²≥0.25
• Sample Size Adequacy: Achieve 80% retention rate (≥240 participants) through 36-month follow-up with complete sleep and cognitive data
• Neuroimaging Correlation: Sleep dysfunction predicts ≥15% additional variance in hippocampal atrophy beyond age-related decline (p<0.005)
• Clinical Relevance: Sleep-based risk stratification model achieves ≥75% sensitivity and ≥70% specificity for predicting MCI conversion within 3 years